INTRODUCTION
Rotavirus (RV) infection is one of the most common causes of diarrhea in young children less than 5 years old across the world, before the vaccine introduction in 2006 [1, 2] . The infection is normally endemic but shows a higher frequency among young children during the winter period, especially in the more temperate climates of the developed world [3] [4] [5] . Severe consequences of RV gastroenteritis (RVGE) are more often observed in children under the age of 2 years, after which a dramatic drop in the number of diarrhea events is noticed [6] . After 5 years of age, children have normally acquired a natural immunity so that RV diarrhea is seldom reported [7] [8] [9] .
RVGE is very contagious and its spread therefore remains difficult to control, even with rigorous application of primary hygienic measures [10] . As a result, the RVGE peaks are well-known as annually recurring public health problems. In Belgium for instance, before the introduction of the RV vaccine, the disease was causing a burden of around 70,000-75,000 diarrhea events per year (community-acquired and hospitalizations) in children under the age of 7 years [11, 12] . The RV infection has some interesting features that make the contagion quite unique. Indeed, RV immunity is built up by successive infection exposures of which the first one is the most severe leading to acute symptoms but the following ones are progressively less severe [9, 13] .
To reduce this public health burden, a radical change in disease prevention should be considered such as the early stimulation of infants' immunity between the ages of 6 and 10 weeks, thus providing protection before a first infection after which repeated exposures may assess a natural boost to immunity. [14, 15] . Although vaccination is recommended by European guidelines [16] and by the World Health Organization [17, 18] , only 4 countries in Western Europe introduced the RV vaccine into their routine immunization schedules soon after the vaccine became available:
Austria, Belgium, Finland, and Luxemburg [19] . By February 2014, national universal RV vaccination recommendations had been implemented in a few additional countries, including Estonia, Germany, Norway, and the United Kingdom (UK) [20] . Studies from Austria [21, 22] , Finland [20, 23] , and Belgium [24] [25] [26] have reported quite impressive reductions in hospitalizations 2-3 years after vaccine introduction combined with a vaccine herd effect. The medium-to long-term effect of the vaccine within the same at-risk group has not often been reported [27, 28] . In the current study, we report about results of Belgium where the vaccine uptake was very high from start ([85% in the first year) and where cohorts of children B5 years of age were followed from 2005 through 2013 (2 years pre-vaccination and 7 years post-vaccination) [29] . Such a long follow-up period should help in better understanding how the vaccine is working in real-life conditions. Hypothesizing that there is only one infection source (the children themselves) and that the vaccine effectiveness remains the same together with a well-maintained high vaccine uptake ([85%) , the RVGE hospitalization rate should decrease year after year, potentially leading to an elimination of the very severe disease cases very soon as disease modelers were speculating [30] . The present study aims to verify this hypothesis by analyzing and comparing the 
Data Analysis
The data were analyzed in two different ways:
• Cross-sectional analysis The number of hospitalizations during the yearly peak periods (January until the end of May) for • Birth cohort analysis The number of hospitalizations during the peak period was noted in the birth cohort for the 1st and for 
Model Simulation
To well-understand the real impact the vaccine has, this can best be achieved by comparing observed results with a model simulation in which we separately control the different aspects that could impact on the outcome (hospital reduction) such as changing the vaccine efficacy (VE) over time, initiating a second source of infection not being affected by the vaccine, changing the vaccine waning rate, or changing the vaccine uptake per year. For doing that comparison we selected from the observed data the birth cohort follow-up data up to the age of 3 years to obtain enough data-points over time.
A time difference equation model was developed based on the initial data collection of the first years of observation. An analysis was then simulated in which the decrease in hospital numbers for the first few years fitted the observed data with fixed parameters over time, a calibration process:
in which: x t is the number of hospitalizations in year t; x r is the residual number of hospitalizations such that x r ¼ gx 0 where g is the fraction of hospitalizations caused by another source of infection; q is a fixed parameter equivalent to the VE; r t is the vaccine coverage rate in year t; x is a fixed parameter reflecting VE waning over time; and t is the time indicator expressed in year units.
With this model, we may easily adjust the shape of the simulated curve changing separately q or the VE, the vaccine uptake (r t ) at specific t time points, the vaccine waning by decreasing x, and the residual disease caused by another source of infection by changing g. Birth Cohort Analysis Table 1 shows the numbers of RV-positive tests by age-group and by year for each peak period A herd effect was maintained after the first 5 years of the vaccination program, as shown by the continued reduction in RV-positive tests seen in children \2 months of age who are too young for vaccination (first row, yellow cells; Table 1) .
A particularly interesting finding in the cohort analysis is that the data do not show any significant additional drop in the early age-groups ([2-12 months and 12 months-2 years) after the large decrease of the first 2 years. This indicates that the rate of decrease in hospitalization changes over time, which indirectly reveals that another factor must influence the process of RV infection in this child population. Figure 3 compares first-year observed results ( Fig. 3a) with simulations of having another source of infection in the population (Fig. 3b) , having no other source of infection in the population (Fig. 3c) , vaccine waning (Fig. 3d) , and having a different vaccine uptake scenario (Fig. 3e ).
Model Simulations
There is a good fit between the observed data and the simulations for the first 3 years when the q-factor in the simulation equation equals 0.5 and no other source of infection was present Fig. 2 Distribution of RV-positive tests by age-group and year. Nbr number, RV rotavirus, mo months, yrs years (Fig. 3c ). Under such scenario we could normally foresee an elimination of the disease over a few years as it was hypothesized by some modelers.
However, a much better overall good fit of the whole observed curve shape (Fig. 3b) was obtained if the additional source of infection with residual disease (g-factor) was introduced in addition to the q-factor. The g-factor was estimated at 12% of the hospitalizations in the equation (R 2 = 0.989; Mann-Whitney U rank-sum test between observed and simulated curve, z stat = 0.368, P = 0.713).
For vaccine waning (Fig. 3d) , we first simulated a decrease of 10% of x per year. To obtain a perfect fit with the observed data the annual waning would have to reach 35%, starting in the second year of vaccination.
Varying the vaccine uptake from 85% to 65%
in the 3rd year doesn't affect the curve (Fig. 3e ) so much as the biggest drop in hospitalization occurs in the first years and what happens thereafter appears having a marginal effect. The point to make here is that any decrease in vaccine uptake later on, cannot explain the observed curve as it is now. 
DISCUSSION
This analysis of medium-to long-term impact of RV vaccination on specific tests measured annually in the same 11 hospital centers in Belgium has identified several interesting features.
First, there is a large reduction in frequency of RV disease during the normal seasonal peak period after vaccination of the first birth cohort had started. The decrease of 70-80% in RV-positive tests, compared with the period of no vaccination, is achieved within 2 years after vaccine introduction. These findings have [25, 32] . After that large initial drop however, subsequent annual decreases are more modest (around 10-15% per age-group). A similar early vaccine effect (the sharp drop in the first year) has been observed in the UK during the first year after the vaccine introduction [33] . The decline is more spectacular during the first year than in the present study. This could be due to the start date of the vaccination campaign in the UK, which was planned by the end of the second quarter the year before the start of the next peak season. In Belgium, vaccination began much closer to the next peak season, namely in the fourth quarter of the year [34] . Second, in addition to the important direct vaccine effect seen in the first vaccinated birth cohort, we also observe, during the same period, a substantial drop in the unvaccinated age-groups (i.e., children too young or too old to be vaccinated, as shown in Table 1 ). This phenomenon clearly indicates the high transmission rate of the virus between the The overall drop in disease events was spectacular during the first two years, because the younger age-groups targeted by the vaccine program are the groups most affected by RV disease (peak incidence rates) and are the highest receivers and transmitters of the virus to other age-groups. Virus transmission within these age-groups and to other age-groups was directly and indirectly reduced by the vaccine.
Once the at-risk group has been vaccinated, herd protection in the older age-groups would be expected to disappear, as children in this group would have been vaccinated when they were younger. This would leave the herd effect being present only in children B2 months of age (who are too young for vaccination) as an additional benefit sustained over time.
With 7 years of real-world observations after vaccine introduction, this study provides information about the likely source of infection of RV disease in the child population. The results split by age-group in Fig. 2 indicate that the role of the vaccine is primarily to stop the spread of the infection within the child population. The vaccine fulfills that task very well, as it induces a high level of herd protection across the different unvaccinated age-groups during the same period. To obtain such a high unlikely that that potential disturbance may impact so heavily the outcome results. In addition, the vaccine coverage rate in Belgium remained stable and quite high during the whole observation period ([86%, [32] ).
These indications of additional sources of infection suggest that the disease and the virus will not be easily eliminated unless the other sources of infection can be targeted by different vaccination strategies.
A cohort analysis illustrates effects within the child population over time, including the dynamics of indirect vaccine impact. This type of investigation is more sensitive and better able to identify the real-world benefit of the vaccine than using VE data obtained through randomized clinical trials, where the control group may be influenced by the herd protection. This may reduce the measured VE, as seen in the European trial [35] . A limitation of the current study is that we do not fully control the denominator of the study, and thus we assume that the target population has not significantly changed over the 9 years of the study period. For a small country like Belgium, with a stable population (the birth cohort may change by less than 0.6% per year), this assumption is reasonable. Another assumption is that no change behavior in testing the children for RV infection appeared over time after the introduction of the vaccine.
CONCLUSIONS
The analysis here presented may provide the evidence for another source of RV infection after the introduction of the RV-vaccine that exists outside the child population such as care-givers at home or day-care centers, even the animal environment. This source appears to be less spectacular in spreading the disease in the child population than the transmission within the age-group. It may also less likely be significantly influenced by vaccination because the current strategy may not directly touch these reservoirs.
The results of this study help to fill an information gap about the impact of RV vaccination over the medium-to long-term.
The main features reported are the sustained reduction in hospitalization. The new finding about different sources of infection in the child population reveals that it may be difficult to reduce the disease to very low levels. A residual disease presence observed over time means that we need to continue to monitor the events each year to detect any new developments. 
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